DiagMMR is designed to be a predictive diagnostic tool that enables preventive follow-up and counselling for affected mutation carriers who are at high risk for developing Lynch syndrome related cancers.

While current Lynch syndrome diagnosis relies heavily on tumor studies, the quantitative DiagMMR method allows carrier diagnosis based on a minimally invasive tissue sample before the person has developed any cancer, without the knowledge and details of an inherited mutation.

The inherent challenges to variant interpretation in genetic testing can be avoided and the conclusive and actionable results removes the burden of uncertainty from both the patients and the treating medical professionals.

LS CancerDiag Ltd is committed to reducing cancer mortality rates with a low-cost, simple diagnostic method that detects an inherited cancer-causing condition prior to cancer. Their vision is to see DiagMMR™ as a new global testing standard in LS diagnostics. Lynch syndrome is the main cause of hereditary colorectal cancers and it also causes a broad spectrum of other tumors. With a significant proportion of the world’s population carrying the Lynch syndrome mutation, there are potentially tens of millions under a severe risk for being affected by LS. Their groundbreaking DiagMMR™ assay is an easy functional test that can be used for diagnosis of MMR deficiency i.e. Lynch syndrome (previously known as Hereditary Non­Polyposis Colorectal Cancer; HNPCC). Their mission is to save lives through an innovation that dramatically simplifies diagnostics of Lynch syndrome by delivering predictive and accurate results with a fast, unique and cost-efficient method globally.

500 proprietary risk assessment algorithms focused on early disease risk detection to improve early disease and diagnosis.

Elevate medical practice by earlier disease detection and improved diagnosis via more accurate data collection, better risk and symptom assessment, faster charting, and increased revenue by higher level E&M billing. Now, achieve better outcomes in less time for more money.

Discover SOAP, a patented and clinically validated, Epic, AthenaHealth, etc. EHR-integrated, conversational AI-powered patient and physician-facing interface for more accurate patient data collection and analysis; an unrelenting focus on improving patient outcomes and eliminating administrative burdens. 

Patented and clinically validated AI-powered new "Gold Standard" of more accurate, truthful and comprehensive patient interviews in less time for more money, risk and symptom assessment, differential diagnosis and note creation.

Patented and clinically validated AI-powered new "Gold Standard" of more accurate, truthful and comprehensive patient interviews in less time for more money, risk and symptom assessment, differential diagnosis and note creation. Less time to provide better care for more money.